
Topic
Medicare Part D
Part D formulary design, IRA negotiated prices, out-of-pocket caps, LIS/Extra Help, and Medicare drug coverage policy.

Pricing & Access· May 24, 2026 · 11 min read

Pricing & Access· May 23, 2026 · 10 min read
DOAC access landscape: Eliquis, Xarelto, Pradaxa, and Savaysa in 2026
By Ran Chen#DOAC#Coverage Access#Prior Authorization

Pricing & Access· May 23, 2026 · 9 min read
Trulicity coverage guide: formulary tiers, prior authorization, and patient assistance
By Ran Chen#GLP-1#Coverage Access#Prior Authorization

Pricing & Access· May 22, 2026 · 15 min read
340B and IRA MFP non-duplication workflow for manufacturer teams

Pipeline· May 22, 2026 · 13 min read
Compendia listing gaps for oncology access before label expansion
By Ran Chen#Oncology#Market Access#Medicare Part D

Pricing & Access· May 22, 2026 · 12 min read
State PDAB launch-risk watchlist for market access teams
By Ran Chen#Drug Pricing#Market Access#Payer Policy

Policy· May 21, 2026 · 8 min read
Medicare Part D redesign 2025-2026: IRA changes and access implications

Pricing & Access· May 18, 2026 · 11 min read
Jardiance vs Farxiga: label, access, and payer coverage compared

Pricing & Access· May 17, 2026 · 10 min read
Farxiga coverage guide: formulary, prior authorization, and what access teams should know

Pricing & Access· May 17, 2026 · 9 min read